NextCure (NASDAQ:NXTC) Trading Up 4.9% – Still a Buy?

NextCure, Inc. (NASDAQ:NXTC)’s share price was up 4.9% during mid-day trading on Wednesday . The stock traded as high as $12.15 and last traded at $11.69. 50,995 shares traded hands during trading, a decline of 21% from the average daily volume of 64,912 shares. The stock had previously closed at $11.14.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on NXTC. LADENBURG THALM/SH SH raised shares of NextCure from a “neutral” rating to a “buy” rating and set a $18.00 price target on the stock in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a research report on Friday, October 31st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, NextCure currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

NextCure Stock Up 4.9%

The firm has a market capitalization of $31.33 million, a P/E ratio of -0.48 and a beta of 1.54. The business’s 50-day simple moving average is $10.04 and its 200 day simple moving average is $7.05.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($3.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.06) by $0.84. Sell-side analysts predict that NextCure, Inc. will post -1.87 earnings per share for the current year.

Hedge Funds Weigh In On NextCure

An institutional investor recently raised its position in NextCure stock. Cable Car Capital LP boosted its stake in NextCure, Inc. (NASDAQ:NXTC) by 13.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 758,141 shares of the company’s stock after purchasing an additional 88,040 shares during the period. Cable Car Capital LP owned about 28.29% of NextCure worth $349,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.